Three New Sites Join HT-001 Trial, GW University Hospital, UC Irvine and Northwell Health
Save time and jump to the most important pieces.
Shares of Indivior PLC (NASDAQ:INDV) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program. Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million. Indivior shares jumped 14.5% to $12.46 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Psyence Biomedical Ltd. (NASDAQ:PBM) rose 157.4% to $1.00 in pre-market trading after the company
TSLA: -8.8% | Tesla shares are trading lower following mixed Q2 earnings. The company also said it expects 2024 vehicle volume growth lower than 2023. HOTH: 95% | Hoth Therapeutics signs Agreement With LTS Therapy Systems To Develop And Manufacture The HT-ALZ Oral Film Prototype In Alzheimer's Disease PRG: 14% | PROG shares are trading higher after the company reported better-than-expected Q2 financial results. Also, the company raised its FY24 guidance above estimates.
NEW YORK, Nov. 20, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient focused biopharmaceutical company, today announced that the Company's Board of Directors approved the purchase of up to $1 million in Bitcoin. "As Bitcoin continues to grow, gaining investor attention and acceptance as a major and primary asset class, we believe that Bitcoin will serve as a strong treasury reserve asset," said Robb Knie, CEO of Hoth. "With recent approval of Bitcoin ETFs and increasing activity from institutional investors, it is a strong addition to our treasury strategy.
NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, is excited to announce highly promising early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that the treatment successfully stabilizes tumor growth with remarkable consistency across subjects, showing potential as an effective therapeutic option in oncology. This study was performed and took place under a sponsored scientific research agreement with NC State University.
NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to announce the granting of a U.S. patent for its pioneering Alzheimer's treatment, HT-ALZ. This milestone patent secures the company's intellectual property rights to its novel therapeutic approach, as Hoth accelerates preparations for clinical trials. HT-ALZ represents a breakthrough in Alzheimer's treatment, specifically targeting the Substance P/Neurokinin-1 Receptor pathway. This pathway is known to
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)
10-Q - Hoth Therapeutics, Inc. (0001711786) (Filer)
8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)